Anna van der Voort - Concepedia

Author

Anna van der Voort

The Netherlands Cancer Institute ORCID

Also Known As

A van der Voort, A. van der Voort, Anna van der Voort

Publications

815

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Reinier de Graaf Hospital Ziekenhuis Groep Twente Oncode Institute Radboud University Nijmegen

About

Anna van der Voort is an author at The Netherlands Cancer Institute specializing in oncology, cancer therapeutics, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	504
2	Health Sciences	2	2	71
3	Engineering	1	1	78
4	Computer Engineering	1	1	78
5	Pathology	1	1	20

Anna van der Voort

Publications

791

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven, The Lancet Oncology Breast OncologyOncologyDual Her2 BlockadePharmacologyBreast Cancer	2018	413
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, JAMA Oncology	2021	130
Experimental modelling and LPV control of a motion system M. Steinbuch, René van de Molengraft, Anna van der Voort Experimental ModellingMotion ControlEngineeringAerospace EngineeringModel-based Control Technique	2004	78
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst, The Lancet Oncology Neoadjuvant Chemotherapy DurationBreast OncologyMedical ImagingMedicineMri-guided Optimisation	2024	36
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven, Journal of Clinical Oncology Breast OncologyOncologyHealth SciencesMedicineMetronomic Therapy	2020	35
Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with dried blood spot sampling: A randomized controlled hybrid implementation trial Herman Veenhof, Job F. M. van Boven, Anna van der Voort, British Journal of Clinical Pharmacology	2020	33
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade Marte C. Liefaard, Anna van der Voort, Maartje van Seijen, npj Breast Cancer	2024	25
Possible missed opportunities for diagnosing colorectal cancer in Dutch primary care: a multimethods approach Daan Brandenbarg, Feikje Groenhof, Ilse M Siewers, British Journal of General Practice	2017	21
Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival Anna van der Voort, Marte C. Liefaard, Mette S. van Ramshorst, The Breast 5-Year SurvivalBreast OncologyOncologyStage IiPathology	2022	20

Page 1